NYSE Files Form 25-NSE for Teva ADS Delisting Following Ordinary Share Exchange
TEVA PHARMACEUTICAL INDUSTRIES LTD
Subscribe to track TEVA
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📢 Form 25-NSE Filing: Teva Pharmaceutical Industries Ltd • Exchange: New York Stock Exchange LLC • Security Delisted: American Depositary Shares (ADSs) • Reason: Mandatory 1-for-1 exchange of ADSs into Ordinary Shares upon termination of ADS program • Impact: ADS listing discontinued; Ordinary Shares remain listed on NYSE • Effective Date: September 14, 2026
Comprehensive Analysis
Overview
On September 14, 2026, the New York Stock Exchange LLC filed a Form 25-NSE notification with the SEC regarding the removal from listing and registration of the American Depositary Shares (ADSs), each representing one Ordinary Share, of Teva Pharmaceutical Industries Ltd (CIK: 0000818686).
Key Details
- Security Affected: American Depositary Shares (CUSIP:
881624209). - Rule Provision: 17 CFR 240.12d2-2(a)(3).
- Corporate Action: Effective September 14, 2026, Teva completed a mandatory 1:1 exchange of its ADSs for Ordinary Shares in connection with the termination of its ADS program.
- Continued Listing: This delisting applies solely to the ADS instrument. The Ordinary Shares of Teva Pharmaceutical Industries Ltd (CUSIP:
M8769Q102) remain listed and traded on the NYSE.
Trading Significance
Low. This is an administrative transition resulting from the termination of the ADS program and the direct listing of Teva's Ordinary Shares on the NYSE, with no adverse impact on the company's exchange-traded status.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.